EARLY DIAGNOSIS AND TREATMENT PRINCIPLES OF HEART FAILURE IN CHILDREN

JOURNAL OF IQRO – ЖУРНАЛ ИҚРО – IQRO JURNALI – volume 18, issue 02, 2025 ISSN: 2181-4341, IMPACT FACTOR ( RESEARCH BIB ) – 7,245, SJIF – 5,431 www.wordlyknowledge.uz ILMIY METODIK JURNAL Ma’mirova Saydiniso Nuriddin qizi Student, Faculty of Pediatrics, Kokand University, Andijan Branch Scientific supervisor: Assoc. Prof. Khankeldiyeva Kh.K. Andijan State Medical Institute EARLY DIAGNOSIS AND TREATMENT PRINCIPLES OF HEART FAILURE IN CHILDREN Annotation: Heart failure in children is a serious and multifactorial clinical syndrome characterized by the heart’s inability to maintain adequate circulation to meet metabolic demands. Unlike in adults, pediatric heart failure often results from congenital structural abnormalities, cardiomyopathies, or myocarditis. Early diagnosis is crucial to prevent irreversible myocardial damage and to improve survival and development outcomes. This article examines the pathophysiological mechanisms, clinical manifestations, diagnostic methods, and modern therapeutic strategies for pediatric heart failure. Special attention is given to the use of echocardiography, electrocardiography, and cardiac biomarkers such as B-type natriuretic peptide (BNP) and NT-proBNP for early detection. The discussion highlights the importance of individualized therapy, combining pharmacologic treatment, nutritional support, and management of precipitating factors. Timely recognition and comprehensive treatment can significantly enhance prognosis, reduce hospitalizations, and improve quality of life for affected children. Key Words: Pediatric cardiology, heart failure, early diagnosis, echocardiography, biomarkers, pharmacotherapy, treatment principles. Main Part Heart failure in pediatric patients develops when the cardiac output is insufficient to maintain systemic and pulmonary circulation. The underlying causes depend on age. In neonates and infants, congenital heart defects such as ventricular septal defect, patent ductus arteriosus, and coarctation of the aorta are predominant. In older children and adolescents, myocarditis, rheumatic heart disease, and dilated cardiomyopathy are common etiological factors. The pathophysiology involves systolic or diastolic dysfunction, neurohormonal activation, and fluid retention leading to pulmonary and systemic congestion. The sympathetic nervous system and renin-angiotensin-aldosterone system become overactivated, causing further myocardial stress and remodeling. These mechanisms contribute to a vicious cycle of cardiac deterioration if not addressed early. Clinical presentation differs by age. Infants usually exhibit feeding difficulties, poor weight gain, tachypnea, diaphoresis, and irritability during feeding. Older children may present with fatigue, dyspnea on exertion, abdominal distension, hepatomegaly, and peripheral edema. Recognition of these symptoms at the early stage is essential to prevent decompensation. The diagnosis is established through a combination of physical findings, instrumental methods, and laboratory investigations. Echocardiography is the principal tool for identifying structural JOURNAL OF IQRO – ЖУРНАЛ ИҚРО – IQRO JURNALI – volume 18, issue 02, 2025 ISSN: 2181-4341, IMPACT FACTOR ( RESEARCH BIB ) – 7,245, SJIF – 5,431 www.wordlyknowledge.uz ILMIY METODIK JURNAL defects, measuring ventricular ejection fraction, and assessing myocardial performance. Electrocardiography provides data on rhythm disturbances and chamber hypertrophy. Chest radiography can show cardiomegaly and pulmonary congestion. Cardiac biomarkers such as BNP and NT-proBNP are now widely used for both diagnosis and monitoring of heart failure severity. Elevated BNP levels correlate with increased ventricular wall stress and are useful in distinguishing heart failure from respiratory conditions with similar symptoms. Treatment of heart failure in children aims to correct the underlying cause, improve hemodynamics, and relieve symptoms. Diuretics such as furosemide are used to eliminate excess fluid and reduce preload. Angiotensin-converting enzyme inhibitors, including captopril or enalapril, decrease afterload and improve cardiac efficiency. Beta-blockers like carvedilol are introduced in chronic stable patients to counteract sympathetic overactivity and enhance ventricular function. In certain cases of systolic dysfunction, digoxin is employed to increase myocardial contractility. Nutritional and supportive therapy are equally important. Adequate caloric intake, control of anemia, and treatment of infections contribute to overall stability. Oxygen therapy and careful fluid management are essential in acute decompensation. In severe cases refractory to medical therapy, mechanical circulatory support or heart transplantation may be necessary. Preventive measures include routine screening of children with congenital heart diseases, close follow-up of those with cardiomyopathies, and early treatment of infections that can lead to myocarditis. Family education regarding symptom recognition and medication adherence is vital to reduce rehospitalization and mortality. Conclusion Heart failure in children is a multifactorial condition that represents a final common pathway for various congenital, acquired, and metabolic heart diseases. The early identification and management of this syndrome are crucial to improving both survival and long-term quality of life. Unlike in adults, where ischemic heart disease predominates, pediatric heart failure is most frequently caused by congenital structural defects, myocarditis, and cardiomyopathies. Because of this etiological diversity, clinical manifestations often vary according to age, making early recognition a significant diagnostic challenge. The prognosis of pediatric heart failure depends directly on the timeliness and accuracy of diagnosis. The use of modern diagnostic techniques — particularly echocardiography, electrocardiography, and laboratory biomarkers such as BNP and NT-proBNP — allows clinicians to identify cardiac dysfunction at subclinical stages. These markers reflect the degree of myocardial stress and are invaluable in differentiating cardiac from respiratory causes of symptoms in children. Regular monitoring of these parameters can predict decompensation before overt clinical deterioration occurs. Treatment strategies should be comprehensive and individualized, addressing both the underlying etiology and secondary hemodynamic consequences. Pharmacological interventions including diuretics, ACE inhibitors, beta-blockers, and digitalis remain the foundation of medical therapy. Their correct and timely use leads to improvement in cardiac performance, reduction of preload and afterload, and attenuation of neurohormonal overactivation. Nutritional support, infection control, and electrolyte balance are also essential components of holistic care. In refractory or end-stage cases, mechanical circulatory support systems and heart transplantation offer lifesaving options. JOURNAL OF IQRO – ЖУРНАЛ ИҚРО – IQRO JURNALI – volume 18, issue 02, 2025 ISSN: 2181-4341, IMPACT FACTOR ( RESEARCH BIB ) – 7,245, SJIF – 5,431 www.wordlyknowledge.uz ILMIY METODIK JURNAL The long-term management of pediatric heart failure requires an integrated, multidisciplinary approach involving pediatric cardiologists, nutritionists, intensivists, and rehabilitation specialists. Parental education and psychosocial support are equally important for adherence to treatment and monitoring of disease progression. Advances in pediatric cardiology, such as the introduction of new inotropic agents, gene therapy, and regenerative medicine, are expected to transform the management of heart failure in the near future. In conclusion, early diagnosis and prompt, evidence-based treatment of heart failure in children can significantly reduce mortality and prevent irreversible cardiac remodeling. Continuous clinical observation, regular echocardiographic evaluation, and biomarker-guided therapy are the key pillars of effective management. The future of pediatric heart failure care lies in precision medicine, where early detection, targeted pharmacotherapy, and innovative technologies converge to ensure that every child with cardiac dysfunction receives timely and individualized care, ultimately improving survival rates and life quality across the pediatric population. Literatures 1. Hsu DT, Pearson GD. Heart failure in children: part I—history, etiology, and pathophysiology. Circ Heart Fail. 2023;16(4):e009801. 2. Rossano JW, et al. Diagnosis and management of pediatric heart failure. J Am Coll Cardiol. 2024;83(7):765–780. 3. Price JF, et al. B-type natriuretic peptide in the diagnosis of pediatric heart failure. Pediatrics. 2022;149(5):e2021054321. 4. Shaddy RE, et al. Treatment advances in pediatric heart failure. Prog Pediatr Cardiol. 2023;67:101512. 5. Исраилова, Г. М., Эшмурадова, С. Т., & Тураев, И. Э. (2010). ГИГИЕНИЧЕСКАЯ ОЦЕНКА ФАКТОРОВ РИСКА ЗАГРЯЗНЕНИЯ МЯСОМОЛОЧНОЙ ПРОДУКЦИИ, ПРОИЗВОДИМОЙ В УСЛОВИЯХ МАЛОВОДЬЯ. Профилактическая и клиническая медицина, (1), 41-43. 6. Nurumbetova, S. (2022). VAIN ASPECTS OF PRACTICAL RELIGIOUS EXAMINATION IN THE INVESTIGATION OF CRIMES RELATED TO PROHIBITED RELIGIOUS MATERIALS. Science and Innovation,1(6), 108-113. 7. Nurumbetova, S. (2023). MODERN OPPORTUNITIES AND PROSPECTS FOR DEVELOPMENT EXPERT-CRIMINALISTIC ACTIVITY. Modern Science and Research,2(9), 415-419. 8. Nurumbetova, S. (2022). ДИНИЙ МАЗМУНДАГИ ТАҚИҚЛАНГАН МАТЕРИАЛЛАР БИЛАН БОҒЛИҚ ЖИНОЯТЛАРНИ ТЕРГОВ ҚИЛИШДА ДИНШУНОСЛИК ЭКСПЕРТИЗАСИНИ ЎТКАЗИШ АМАЛИЁТИНИНГ МУҲИМ ЖИҲАТЛАРИ. Science and innovation,1(C6), 108-113. 9. Khalimovich, R. B. (2023). Simplification of criminal proceedings: concept, content and importance. World Bulletin of Management and Law,18, 51-54. 10. Norkulov, D., Zikirova, N., Niyozova, N., Makhkamov, U., & Sattarov, I. (2020). BASICS OF ONLINE TEACHING, USAGE ANDIMPLEMENTATIONPROCESS. Systematic Reviews in Pharmacy,11(11). 11. Niyozova, N. (2023). RELEVANCE AND IMPORTANCE OF HIGHER EDUCATION NURSE TRAINING. Web of Scientists and Scholars: Journal of Multidisciplinary Research,1(8), 93-94. 12. Kantor PF, et al. Contemporary outcomes and management of pediatric dilated cardiomyopathy. Eur Heart J. 2024;45(3):311–325.